ORAMED PHARMACEUTICALS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
ORAMED PHARMACEUTICALS INC. (ORMP) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $27.94 million as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2026-03-26
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $27.94M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $27.29M.
- 2025-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $26.86M.
- 2013-05-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $689.45K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2025-12-31 | $27.94M 10-K · filed 2026-03-26 |
| 2025-09-30 | $27.29M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $26.86M 10-Q · filed 2025-08-14 |
| 2013-05-31 | $689.45K 10-Q · filed 2013-07-17 |
| 2013-02-28 | $800.85K 10-Q · filed 2013-04-11 |
| 2012-11-30 | $747.15K 10-Q · filed 2012-12-26 |
| 2011-08-31 | $384.56K 10-K · filed 2013-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |